“We Are On The Cusp Of A Real Revolution”: OHC Rare Disease Center Boosts Innovation

In this episode of the China biopharma English-language podcast, Xu Hu talks about recently China releasing two guidelines related to CAR-T therapies within a month and the strategic position that the country puts its cell therapy sector. The Pink Sheet stories related to this episode: CAR-T Guidelines Signal China’s Next Phase Of Cell Therapy Regulatory System Building CAR-Ts Win Big In New China Drug Coverage Lists

A legal firm’s perspective on how the UK should evolve its medtech regulatory system, global harmonization and opportunities to embed best practice AI.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年3月27当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 默克公司力推Terns及其他交易；勃林格殷格翰对欧洲创新环境不佳的警示；科伦与默克的协议如何改变了中国的交易格局；神经科学研发重振旗鼓；以及美国新的低密度脂蛋白胆固醇（LDL-C）指南与药物成本。

In this episode of HBW Insight’s Over the Counter, we’re digging into one of the most talked‑about themes in consumer health right now: longevity. We’re joined by Magda Starula, Health and Beauty Research Analyst at Euromonitor International, to unpack what “healthy longevity” really means, and why it’s quickly moving from niche concept to mainstream commercial opportunity for OTC. We explore how the focus is shifting from simply living longer to staying healthier for longer, what that means across different life stages, and where consumer healthcare brands are best placed to win.

Audio roundup of selected biopharma industry content from Scrip over the business week ended Mar.27, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – Merck’s case for Terns and more deals; Boehringer’s warning on innovation-unfriendly Europe; how Kelun-Merck pact changed China deal-making; Story Link : https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-KYHAYYDQKVF2BPXKKKMZ2J4GA4/

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider US Food and Drug Administration Commissioner Martin Makary’s first year in office, including the issues that shaped his tenure (:32), his biggest policy accomplishments (14:12), issues that could emerge in his second year (19:35), and when Makary’s term could end (22:52). #pharma #business #FDA More On These Topics From The Pink Sheet US FDA Commissioner Makary’s ‘Bold’ Year 1 Reforms Clouded By Staff Churn, Process Issues: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fda-commissioner-makarys-bold-year-1-reforms-clouded-by-staff-churn-process-issues-BM6PHO3AWNBWXHL5UAJI4YE7TQ/ His Own Words: FDA Commissioner Martin Makary On His First Year Achievements And Challenges: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/his-own-words-fda-commissioner-martin-makary-on US FDA Commissioner Martin Makary’s Eventful First Year: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fda-commissioner-martin-makarys-eventful-first-year-5KU6I3ATTBHIDKFLBKZDWJ5XHA/

Lupin’s CEO Vinita Gupta and managing director Nilesh Gupta speak with Citeline’s senior editor Vibha Ravi about their plans for first-in-class and best-in-class assets including GLP-1 receptor agonists, the defining influence of their father D B Gupta on them, as well as the company’s ethos and future growth strategy.

Lupin’s CEO Vinita Gupta and managing director Nilesh Gupta speak with Citeline’s senior editor Vibha Ravi about their plans for first-in-class and best-in-class assets including GLP-1 receptor agonists, the defining influence of their father D B Gupta on them, as well as the company’s ethos and future growth strategy.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年3月20日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期要闻: 今年将有众多重磅药物失去市场主导地位; 司美格鲁肽在印度的命运；跨国药企不再满足于单纯的中国授权； Almirall瞄准中国皮肤科资产；欧盟被敦促恢复生物制药竞争力。 Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-KZ6RVPJK6BAADJKFNBUNOTMB6M/ Playlist: on.soundcloud.com/gnr7PaOwflNKiAO7QX

Audio roundup of selected biopharma industry content from Scrip over the business week ended Mar.13, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools. This time – many blockbusters to fade this year: semaglutide’s India reckoning; multinationals look beyond simple China licensing; Almirall eyes China dermatology assets; EU urged to restore biopharma competitiveness. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-KZ6RVPJK6BAADJKFNBUNOTMB6M/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things